Sona Nanotech raises US$1.83M in over-subscribed private placement for cancer therapy
What's the deal? Sona NanotechDealroom has a profile for this one. Try Dealroom →, a Halifax-based nanotechnology company, has closed an over-subscribed private placement raising US$1.85M in gross proceeds. It issued 8,423,372 common shares at US$0.22 each, with a four-month-and-one-day hold period.
What's the endgame? Sona is developing Targeted Hyperthermia, a photothermal cancer therapy that uses infrared light absorbed by gold nanorods to heat and shrink solid tumours. The company will use the net proceeds to advance clinical studies and research on the treatment, plus general working capital.
How it works: The therapy delivers heat of 42–48°C to tumours, which stimulates the immune system, shrinks tumours, and inactivates cancer stem cells. Sona's gold nanorods are free of CTAB, a compound that carries toxicity risks in other gold nanorod technologies used in medicine.
Worth noting: Company directors subscribed for 300,000 shares, a related-party transaction under Canadian securities rules. Sona relied on exemptions from formal valuation and minority approval requirements, as the related-party portion did not exceed 25% of its market capitalisation.
The signal: The raise, first announced on 31 July 2026, marks a step-up for Sona as it pushes its oncology work toward clinical advancement. For a company converting nanoparticle manufacturing into both cancer therapies and diagnostics, the financing keeps its lead treatment moving toward trials.
Read more: Stockwatch
Image credit: Generated with Gemini
